This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Pompe Disease
  • /
  • Gene Transfer Study in Patients With Late Onset Po...
Clinical trial

Gene Transfer Study in Patients With Late Onset Pompe Disease (FORTIS)

Read time: 1 mins
Last updated:19th Apr 2023
Status: Recruiting
Identifier: NCT04174105
Gene Transfer Study in Patients With Late Onset Pompe Disease (FORTIS)


Brief Summary:

This is a phase 1/2 open-label, ascending dose, multicenter clinical study to evaluate the safety and efficacy of AT845 in adult (aged ≥ 18 years) subjects, ambulatory or nonambulatory, with Late Onset Pompe Disease (LOPD).

Detailed Description:
This study (FORTIS) will evaluate the safety and efficacy of an investigational gene replacement therapy, AT845, in adult subjects with LOPD. Subjects will receive a single dose of AT845 delivered via intravenous (IV) infusion.

Up to 3 nominal dose levels of AT845 are planned to be evaluated in this study. A single AT845 administration via IV infusion is planned for each subject. The initial dosing cohort received a single dose of 3x10^13 vg/kg of AT845. The second dose cohort will receive a single dose of 6×10^13 vg/kg. The third dose cohort will receive a single dose of 1×10^14 vg/kg. Dose escalation between cohorts will be based on evaluations of safety and in consultation with the independent DMC.

There will be a core observation period of 48 weeks with scheduled visits and assessments. Following the conclusion of the core observation period, subjects will be seen every 6 months for a safety follow-up visit for up to 5 years postdose.


Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 12 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Up to 3 nominal dose levels of AT845 are planned to be evaluated in this study. A single AT845 administration via IV infusion is planned for each subject. The initial dosing cohort received a single dose of 3×10^13 vg/kg. The second dose cohort will receive a single dose of 6×10^13 vg/kg. The third dose cohort will receive a single dose of 1×10^14 vg/kg. Dose escalation between cohorts will be based on evaluations of safety and in consultation with the independent DMC.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
Actual Study Start Date: October 27, 2020
Estimated Primary Completion Date: December 31, 2024
Estimated Study Completion Date: November 30, 2028

Arm:
- Experimental: Initial Dose Cohort
- Experimental: Second Dose Cohort
- Experimental: Third Dose Cohort


Category Value
Study type(s) Interventional
Estimated enrolment 12
Actual Study start date 27 October 2020
Estimated study completion date 30 September 2021

View full details